AsiaIPEX is a one-stop-shop for players in the IP industry, facilitating IP trade and connection to the IP world. Whether you are a patent owner interested in selling your IP, or a manufacturer looking to buy technologies to upgrade your operation, you will find the portal a useful resource.

Induced Pluripotent Stem Cells (iPSCs) for precise, low cost schizophrenia modeling

Summary
Schizophrenia is a complex neurological disorder. Current therapies are limited to disease management, as a basic understanding of the underlying cellular defects remains unavailable. While the microdeletion 22q11.2 is known to be associated with schizophrenia, a human cellular model has yet to be established. Although animal models have been used to study the function of this genetic region, they do not fully mimic the disease as it presents in humans, forcing researchers to rely on brain recordings with poor resolution. This technology describes a series of human induced pluripotent stem cells (iPSCs), stem cells that have been derived from adult tissue, from schizophrenic patients bearing the microdeletion. As 22q11.2 is the only microdeletion known to correlate with psychiatric disorders, these cells represent the most precise cellular model of human schizophrenia to date. Once iPSCs lines have been generated, they can be propagated indefinitely, allowing them to be a great tool in schizophrenia drug screening and are more cost efficient than animal models. As such, this technology provides a robust, low cost, and highly accurate method of studying the pathophysiology of schizophrenia.
Technology Benefits
Can establish causative association between microdeletion and schizophreniaUtilizes cells from humans over animal modelsiPSCs cell lines can be propagated indefinitely and shared easilyApplicable to other psychiatric disorders involving 22q11.2 microdeletion Patent information:Tech Ventures Reference: IR CU15262
Technology Application
Basic research tool for 22q11.2 characterizationDrug screening tool for schizophrenia fieldBasic research tool for other 22q11.2-positive psychiatric disorders, such as Autism
Detailed Technology Description
None
*Abstract
None
*Inquiry
Peter GolikovColumbia Technology VenturesTel: (212) 854-8444Email: TechTransfer@columbia.edu
*IR
CU15262
*Principal Investigator
*Publications
Drew LJ, Crabtree GW, Markx S, Stark KL, Chaverneff F, Xu B, Mukai J, Fenelon K, Hsu PK, Gogos JA, Karayiorgou M. "The 22q11.2 microdeletion: fifteen years of insights into the genetic and neural complexity of psychiatric disorders." Int J Dev Neurosci. 2011 May;29(3):259-81.
Country/Region
USA

For more information, please click Here
Mobile Device